Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189171 | 0.90 | PTGS2 (0.38) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL10189167 | 0.88 | PTGS2 (0.52) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL10189174 | 0.88 | PTGS2 (0.37) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL10188872 | 0.85 | PTGS2 (0.57) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL616692 | 0.84 | MEN1 (0.50) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL10189176 | 0.84 | KDM4E (0.38) | PTGS2HSP90AA1MEN1KMT2A | |
| SCHEMBL10188805 | 0.82 | CCNC (0.38) | PTGS2HSP90AA1HSP90AB1 | |
| SCHEMBL616208 | 0.76 | MEN1 (0.47) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL12338543 | 0.76 | MEN1 (0.57) | HSP90AA1HSP90AB1MEN1KMT2AGAA | |
| SCHEMBL615667 | 0.76 | MEN1 (0.51) | PTGS2HSP90AA1HSP90AB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885HSP90AA1 289/4885HSP90AB1 161/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885HSP90AA1 289/4885HSP90AB1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.